Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

Hypothyroidism related to immunotherapy in elderly adults: Analysis of a Colombian oncology cohort. Use of steroid-sparing agents (SSAs) for immune-related adverse events (irAEs) in patients (pts) ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition that leads to reddening of the skin and the formation of painful and intensely itchy chronic lesions and blisters ...

Sanofi has unveiled plans to invest “at least” $20bn into the US by 2030, with the commitment including a significant ...

This PrimeView highlights the mechanisms of bullous pemphigoid and summarizes the epidemiology, diagnosis and management of this disease. It accompanies the Primer article on this topic by ...

The story of chronic itch and its impact on quality of life is one dermatologists have heard often. Until recently, treatment ...

As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. From January through May 2025, the U.S. regulatory agency has approved ...

A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...

Erythema migrans and erythema multiforme both cause target- or bull’s-eye-shaped lesions. Erythema migrans is due to Lyme disease. Erythema multiforme is an immune-mediated hypersensitivity skin ...